Related Experiment Video

Updated: Jun 18, 2026

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

Using cytokines to treat cervical intraepithelial and invasive neoplasia

Nelson R Tirone1, Márcia A Michelin, Eddie F C Murta

  • 1Oncology Research Institute (IPON), Federal University of the Triângulo Mineiro (UFTM), Brazil.

Recent Patents on Anti-Cancer Drug Discovery
|December 8, 2009
PubMed

Insights

Harnessing cytokines like Interferon-alpha (IFN-alpha) offers a promising strategy for cancer therapy by stimulating the immune system to target neoplastic cells. This review explores patents on cytokine and peptide therapies for cervical cancer and precancerous lesions.

Area of Science:

  • Immunology and Oncology
  • Biotechnology and Therapeutics

Background:

  • Manipulating the immune system to eliminate neoplastic cells is a significant research challenge.
  • Cytokines, such as Interferon-alpha (IFN-alpha), are immunomodulatory agents with demonstrated anti-proliferative effects.
  • IFN-alpha has a history of clinical use in treating infectious diseases, chronic conditions, and various cancers.

Purpose of the Study:

  • To review patents concerning cytokine and peptide-based therapies for cervical intraepithelial neoplasias (CIN) and cervical cancer.
  • To highlight the specific role and application of IFN-alpha in these therapeutic strategies.

Main Methods:

  • Literature review of patents focusing on immunotherapies for cervical cancer.
  • Analysis of patents related to cytokine and peptide applications in oncology.
  • Specific focus on patents involving Interferon-alpha (IFN-alpha).

Main Results:

  • Identified various patents detailing the use of cytokines and peptides as therapeutic agents.
  • Confirmed the documented use of IFN-alpha in preclinical and clinical settings for cancer treatment.
  • Patents cover diverse approaches to leveraging immunostimulants for cervical neoplasia.

Conclusions:

  • Cytokine and peptide therapies, particularly those involving IFN-alpha, represent a significant area of patented innovation for cervical cancer.
  • Further research and development in this field hold potential for novel immunotherapeutic strategies against cervical malignancies.

More Related Videos

Generation and Genetic Manipulation of Human Cervical Organoids10:29

Generation and Genetic Manipulation of Human Cervical Organoids

Published on: March 10, 2026

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...